- Conditions
- Metastatic Carcinoma, Metastatic Sarcoma, Metastatic Lymphoma
- Interventions
- 2.4 mg/kg α-TEA, 4.8 mg/kg α-TEA, 8.0 mg/kg α-TEA, 9.6 mg/kg α-TEA, 12 mg/kg α-TEA, 16.8 mg/kg α-TEA, 19.2 mg/kg α-TEA, 22.3 mg/kg α-TEA, 26.8 mg/kg α-TEA
- Drug
- Lead sponsor
- Providence Health & Services
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 5
- States / cities
- Clackamas, Oregon • Newberg, Oregon • Oregon City, Oregon + 1 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–2
of 2
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Anatomic Stage IV Breast Cancer AJCC v8, HER2 Positive Breast Carcinoma, Metastatic Breast Carcinoma, Refractory Breast Carcinoma
- Interventions
- Alpha-tocopheryloxyacetic Acid, Trastuzumab
- Drug · Biological
- Lead sponsor
- Veana Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2030
- U.S. locations
- 2
- States / cities
- Portland, Oregon • Seattle, Washington